Skip to main content

Table 3 Key clinical trials of EphA2 targeted therapy in cancer

From: Targeting EphA2 in cancer

Agent or approaches Trial identifier Study characteristics Intervention Status
MEDI-547 NCT00796055 Phase 1, n = 6
EphA2-positive solid tumor
IV infusion with MEDI-547 0.08 mg/kg on day 1 of 21-day cycle
Primary outcome: safety and tolerability
Terminated
DS-8895a NCT02252211 Phase 1, n = 9
EphA2-positive solid tumor
Infusion with ^89Zr-Df-DS-8895a 0.2 mg/kg i.v on day 1. DS-8895a 1, 3, or 10 mg/kg on days 8 and 22, and ^89Zr-Df-DS-8895a 1, 3, or 10 mg/kg on day 36
Primary outcome: toxicity
Completed
DS-8895a NCT02004717 Phase 1, n = 37
Solid tumor
Step 1: IV infusion with DS-8895a 0.1, 0.3, 1, 5, 10, or 20 mg/kg on day 1 of 14-day cycle; step 2: IV infusion with DS-8895a 20 mg/kg on day 1 of 14-day cycle
Primary outcome: toxicity, serum pharmacokinetics
Completed
CAR-T cell NCT02575261 Phase 1/2, n = 60
EphA2-positive glioma
Primary outcome: effectiveness Completed
CAR-T cell NCT03423992 Phase 1, n = 100
Recurrent glioma
Primary outcome: adverse events Ongoing
BT5528 NCT04180371 Phase 1/2, n = 152
Solid tumor
IV infusion of BT5528 once a week (days 1, 8, 15, and 22) on a 4-week cycle with or without 480 mg nivolumab
Primary outcome: safety, MDT
Ongoing
SiRNA-EphA2-DOPC NCT01591356 Phase 1, n = 40
Advanced solid tumor
IV infusion of siRNA-EphA2-DOPC on days 1 and 4 of 21-day cycle
Primary outcome: safety, MDT, and ORR
Ongoing
MM-310 NCT03076372 Phase 1, n = 34
Solid tumor
IV infusion of MM-310 on day 1 of 21-day cycle
Primary outcome: MDT
Ongoing
Vaccine NCT02754362 Phase 2, n = 30
Recurrent glioblastoma
Block 1: bevacizumab every 2 weeks for 2 doses; block 2: vaccine + poly-ICLC + bevacizumab on weeks 1, 3, 5, and 7; block 3: vaccine + poly-ICLC monthly and bevacizumab every 2 weeks for 10 months
Primary outcome: immune response, tumor response
Active, not recruiting